Matt Kalnik wants to make smoking less addictive.
His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. The businesses is looking to raise between $5 million and $10 million to run over the next two years and get its lead candidate to clinical trials.
{iframe}https://www.bizjournals.com/washington/news/2019/02/13/a-gaitherburg-biotech-is-raising-millions-to-treat.html?b=1550085964%5E21426969{/iframe}